NEW YORK & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Ajax Therapeutics, Inc., a biopharmaceutical company developing next generation JAK inhibitors for patients with myeloproliferative neoplasms (MPNs), ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Aviceda Therapeutics (“Aviceda”), a private, clinical-stage biotech company focused on developing next-generation immunomodulators with a proprietary High Affinity ...

– Financing led by RA Capital Management with participation from existing investors and additional new investors, including AstraZeneca and Bristol Myers Squibb – SOUTH SAN FRANCISCO, ...